NO20044749L - Stabilisert naturlig cannabinoidformulering - Google Patents

Stabilisert naturlig cannabinoidformulering

Info

Publication number
NO20044749L
NO20044749L NO20044749A NO20044749A NO20044749L NO 20044749 L NO20044749 L NO 20044749L NO 20044749 A NO20044749 A NO 20044749A NO 20044749 A NO20044749 A NO 20044749A NO 20044749 L NO20044749 L NO 20044749L
Authority
NO
Norway
Prior art keywords
sugar
drying
natural cannabinoid
mixture
cannabinoid formulation
Prior art date
Application number
NO20044749A
Other languages
English (en)
Norwegian (no)
Inventor
Henderik W Frijlink
Anko Eissens
Dirk J Van Drooge
Wouter L J Hinrichs
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20044749L publication Critical patent/NO20044749L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20044749A 2002-04-03 2004-11-02 Stabilisert naturlig cannabinoidformulering NO20044749L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36961302P 2002-04-03 2002-04-03
EP02076339 2002-04-04
PCT/EP2003/050087 WO2003082246A1 (en) 2002-04-03 2003-04-02 Stabilized natural cannabinoid formulation

Publications (1)

Publication Number Publication Date
NO20044749L true NO20044749L (no) 2005-01-03

Family

ID=28676390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044749A NO20044749L (no) 2002-04-03 2004-11-02 Stabilisert naturlig cannabinoidformulering

Country Status (16)

Country Link
EP (1) EP1492503B1 (pl)
JP (1) JP4491241B2 (pl)
CN (1) CN100592903C (pl)
AT (1) ATE413862T1 (pl)
AU (1) AU2003240759B2 (pl)
BR (1) BR0308779A (pl)
CA (1) CA2480270A1 (pl)
DE (1) DE60324668D1 (pl)
DK (1) DK1492503T3 (pl)
ES (1) ES2316759T3 (pl)
HR (1) HRP20040816A2 (pl)
MX (1) MXPA04009673A (pl)
NO (1) NO20044749L (pl)
PL (1) PL209134B1 (pl)
RU (1) RU2311178C2 (pl)
WO (1) WO2003082246A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
NZ706991A (en) 2010-03-29 2016-08-26 Ferring Bv A fast dissolving pharmaceutical composition
RU2633640C2 (ru) 2011-09-16 2017-10-16 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
AU2017210319A1 (en) * 2016-01-20 2018-08-23 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
WO2022036462A1 (en) * 2020-08-21 2022-02-24 Organigram Inc. Buccal dosage forms comprising oligosaccharides
WO2023224960A1 (en) * 2022-05-17 2023-11-23 Orcosa Inc. Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.

Also Published As

Publication number Publication date
JP2005521710A (ja) 2005-07-21
AU2003240759A1 (en) 2003-10-13
DK1492503T3 (da) 2009-03-09
HRP20040816A2 (en) 2005-06-30
PL372921A1 (pl) 2005-08-08
JP4491241B2 (ja) 2010-06-30
CN1642527A (zh) 2005-07-20
HK1078458A1 (zh) 2006-03-17
BR0308779A (pt) 2004-12-28
CA2480270A1 (en) 2003-10-09
ES2316759T3 (es) 2009-04-16
ATE413862T1 (de) 2008-11-15
EP1492503B1 (en) 2008-11-12
CN100592903C (zh) 2010-03-03
RU2311178C2 (ru) 2007-11-27
WO2003082246A1 (en) 2003-10-09
PL209134B1 (pl) 2011-07-29
DE60324668D1 (de) 2008-12-24
AU2003240759B2 (en) 2008-02-14
MXPA04009673A (es) 2005-01-11
EP1492503A1 (en) 2005-01-05
RU2004132190A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
NO20044749L (no) Stabilisert naturlig cannabinoidformulering
Al-Mustafa et al. Antioxidant activity of some Jordanian medicinal plants used traditionally for treatment of diabetes
NO20012610L (no) Derivat av kardanol og anvendelser derav
García-Márquez et al. Effect of solvent-temperature extraction conditions on the initial antioxidant activity and total phenolic content of muitle extracts and their decay upon storage at different pH
NO961718L (no) Stabilisert prostaglandin E1
NO20051998L (no) Torke prosess
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
HU9904549A (en) Vaccines
NO954329L (no) Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel
MX9306133A (es) Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
NO942899L (no) Stabiliserte, radiofarmasöytiske sett
ATE357638T1 (de) Kammer für eine gefriertrocknungseinrichtung
NO922246L (no) Matvare-modifiserende preparat og fremgangsmaate for fremstilling derav
NO934289L (no) Stabilisert superoksyd-dismutase (SOD)-blanding
Kimel et al. Hplc-Dad-Esi/Ms Analysis of Arnica Tm Constituents
Brikenstein et al. Optimization of Trimming Techniques for Enhancing Cannabinoid and Terpene Content in Medical Cannabis Inflorescences
Vidal‐Quist et al. Quality control of house dust mite extracts by broad‐spectrum profiling of allergen‐related enzymatic activities
Mylnikov et al. Rubus fruit juices affect lipid peroxidation in a Drosophila melanogaster model in vivo
NO912118D0 (no) Avgrenet araban og dets anvendelse som fetterstatning.
Jerkovic et al. Stilbenic profile of cocoa liquors from different origins determined by RP-HPLC-APCI (+)-MS/MS. Detection of a new resveratrol hexoside
Brocklehurst et al. Electronic spectra of the isomeric 4-benzylidene-2-phenyl-Δ2-oxazolin-5-ones and the products of their reaction with nucleophiles including α-chymotrypsin: Kinetics of the hydrolysis of the isomeric enzyme derivatives
Wirtz et al. Tyrosine and phenylalanine concentrations in haemolymph and tissues of the American cockroach, Periplaneta americana, during metamorphosis
Stein A comparison of some natural and synthetic melanins
Khammee et al. Gas chromatography–mass spectrometry analysis, in vitro activities, and in silico molecular docking of major components of michelia alba dc essential oil and scented extracts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application